The American Association for Cancer Research (AACR) has launched an international initiative called the AACR Project Genomics, Evidence, Neoplasia, Information, Exchange ( GENIE).
The project brings together seven global leaders in genomic sequencing with two informatics partners to aggregate participants’ clinical-grade sequencing data to improve patient treatment decisions and catalyze clinical and translational research.
The seven founding members of the consortium and phase 1 participants are:
- The Center for Personalized Cancer Treatment, Utrecht, Netherlands;
- Dana-Farber Cancer Institute, Boston;
- Institut Gustave Roussy, Villejuif, France;
- Johns Hopkins University's Sidney Kimmel Comprehensive Cancer Center, Baltimore;
- Memorial Sloan Kettering Cancer Center, New York;
- Princess Margaret Cancer Centre, Toronto; and
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
The two informatics partners are:
“The need for AACR Project GENIE is great,” said Charles L. Sawyers, MD, AACR Project GENIE Steering Committee chairperson, 2015-2017, in a release. “Numerous factors are driving an increase in the amount of genomic data available for analysis; however, these data are typically insufficient in number or lack the necessary clinical outcomes data to be clinically meaningful. Thus, to effectively benefit patients, the genomic and clinical outcomes data from as many institutions as is practical should be combined through a data-sharing initiative, such as AACR Project GENIE.”
AACR Project GENIE will pool existing and ongoing Clinical Laboratory Improvement Amendments (CLIA) and International Organization for Standardization (ISO)-certified sequencing data from the participating institutions into a single registry and linking these data with select longitudinal clinical outcomes. All project data will be made open-access following defined periods of project exclusivity, and the initial genomic data set will be publicly available on Nov. 6, 2016.
The AACR Project GENIE registry already contains more than 17,000 genomic records. This registry is unique in that it is enriched in late-stage cancers and contains only clinical-grade sequencing data on which clinical decisions have been made, according to the organization.